555

Pharming Clinical Trials

Please see below to learn more about our current and prior clinical trials.

[Phase 3] Study of Efficacy of CDZ173 in Patients with APDS/PASLI*

Status: completed
Study type: Interventional
Key dates: Start date Aug 24, 2015

[Phase3] Extension to Study of Efficacy of CDZ173 in Patients with APDS/PASLI*

Status: Active, not recruiting
Study type: Interventional
Key dates: Start date Sept 8, 2016

If interested in participating or to learn
more click here.

“there are many reasons to choose to join a clinical trial. Some join a trial because the treatments they have tried for their health problem did not work. Others participate because there is no treatment for their health problem. By being part of a clinical trial, participants may find out about new treatments before they are widely available”1

– NIH

[Phase 3] Pediatric Patients Aged 4 – 11 Years with APDS*

Status: Not yet recruiting
Study type: Interventional
Key dates: Start date Aug 31, 2022

If interested in participating or to learn more click here.

Pharming is committed to bringing new therapies to people with rare diseases and will work closely with regulatory authorities across the globe in an effort to make this innovative option available to physicians who care for patients with APDS
– Anurag Relan – Chief Medical Officer,
Pharming N.V.

[Phase 3] Pediatric Patients Aged 4 – 11 Years with APDS*

Status: Not yet recruiting
Study type: Interventional
Key dates: Start date Aug 31, 2022

If interested in participating or to learn more click here.

Pharming is committed to bringing new therapies to people with rare diseases and will work closely with regulatory authorities across the globe in an effort to make this innovative option available to physicians who care for patients with APDS
– Anurag Relan – Chief Medical Officer,
Pharming N.V.

If you are a physician and would like more information, or are interested in participating in clinical trials, sign up here.

To learn more contact Pharming’s Medical Information department via the email below.
Email: pharmingmc@eversana.com

* The safety and efficacy of CDZ173 (Leniolisib) has not been established. There is no guarantee that it will receive health authority approval or become commercially available in any country for the use being investigated.

Stay informed

Sign up for APDS updates

  1. “What Are Clinical Trials and Studies?” National Institute on Aging, U.S. Department of Health and Human Services, 9 Apr. 2020,
    https://www.nia.nih.gov/health/what-are-clinical-trials-and-studies